Company Filing History:
Years Active: 2025
Title: The Innovative Contributions of Ho Cho
Introduction
Ho Cho is a notable inventor based in Summit, NJ (US), recognized for his significant contributions to the field of biotechnology. With a focus on engineering antibodies, he has made strides in developing targeted therapies for cancer treatment. His work exemplifies the intersection of innovation and medical science.
Latest Patents
Ho Cho holds a patent for the engineering of an antibody designed for tumor-selective binding of CD47. This innovative antibody comprises at least one Fab portion that binds CD47 and another that binds the tumor-associated antigen (TAA) CD20. The unique design allows the Fab portion that binds CD47 to exhibit low affinity for CD47, while the Fab portion that binds CD20 demonstrates high affinity for CD20. This selective binding mechanism enables the antibody to block CD47 interaction with SIRPα in tumor cells, while showing no substantial binding to CD47 in normal cells.
Career Highlights
Ho Cho is currently employed at Celgene Corporation, where he continues to advance his research in antibody engineering. His work is pivotal in the development of therapies that could potentially improve cancer treatment outcomes.
Collaborations
Ho Cho collaborates with esteemed colleagues, including Haralambos Hadjivassiliou and Dan Zhu, who contribute to his research endeavors and enhance the innovative environment at Celgene Corporation.
Conclusion
Ho Cho's contributions to antibody engineering represent a significant advancement in targeted cancer therapies. His innovative approach and collaborative spirit continue to drive progress in the field of biotechnology.